SCHEMBL16408387

SCHEMBL16408387

NS(=O)(=O)c1cccc(NC(=O)c2c(Oc3ccccc3Cl)cccc2C(F)(F)F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16398458 0.91 — —
SCHEMBL29918926 0.91 — —
SCHEMBL16408390 0.88 — —
SCHEMBL17791076 0.88 — —
SCHEMBL17791072 0.88 — —
SCHEMBL16408383 0.87 — —
SCHEMBL17791073 0.85 — —
SCHEMBL16408300 0.83 — —
SCHEMBL17791103 0.83 — —
SCHEMBL16408385 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11203571-B2 Sulfonamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-12-21 — — US claimed
EP-3022175-B1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2017-11-08 — — EP claimed
US-11203571-B2 Sulfonamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-12-21 — — US disclosed
EP-3022175-B1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2017-11-08 — — EP disclosed
EP-3022175-B1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMA (US) 2017-11-08 — — EP disclosed
US-20160152561-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2016-06-02 — — US disclosed
US-20160152561-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2016-06-02 — — US disclosed
WO-2015010065-A1 SULFONAMIDES AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-01-22 — — WO disclosed
Send feedback